technologyScore 70/100Watch
Hassabis: Isomorphic Labs' full AI drug design engine 5-10 years away; clinical trials remain the bottleneck
“I think we'll have that whole drug design engine ready in, you know, the next 5 plus 5 to 10 years. The next problem is the clinical trials still take many, many years, right?”
Why it matters
This is a first-party roadmap timeline from Hassabis (founder of Isomorphic Labs, CEO of Google DeepMind) for when a complete AI-driven drug design platform will exist, and it explicitly identifies clinical trial execution — not molecule design — as the remaining rate-limiter. It calibrates the competitive clock for the whole AI drug discovery sector.
Investment implication
Tempers near-term commercialization expectations for AI drug discovery names (e.g., Recursion, Schrödinger) and for Alphabet's (GOOGL) Isomorphic Labs exposure; suggests near-term value accrues to players that can accelerate or de-risk clinical trials rather than pure in-silico design platforms.